Europe Considers Buying 300 Million Coronavirus Vaccine Doses From BioNTech and Pfizer

Pfizer and BioNTech SE announced on September 9, 2020, that they had concluded talks with the European Commission for a proposed supply of 200 million doses of their investigational BNT162 mRNA-based vaccine candidate that is targeted against the SARS-CoV-2 coronavirus, to European Union (EU) Member States, with an option for purchase an additional 100 million vaccine doses.

The deliveries of the BNT162 vaccine would 'start by the end of 2020, subject to clinical success and regulatory authorization,' stated these companies. If regulatory approval for the BNT162b2 vaccine candidate is received, the European Commission would lead the process for the allocation of the vaccine doses among the 27 EU Member States.

Vaccine doses for Europe would be produced in BioNTech’s German manufacturing sites, as well as in Pfizer’s manufacturing site in located Belgium.

In a late-stage clinical trial, Pfizer and BioNTech are studying a 30µg dose level in a 2-dose regimen among up to 30,000 participants aged 18 to 85 years.